×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Alk expects to launch new allergy tablet in U.S. in 2017
Yahoo Lifestyle Canada
Danish pharmaceutical group Alk Abello expects to start selling its new dust mite allergy tablet in Europe and Japan around the end 2015 with the U.S....
3 days ago
ALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin Allergy
PR Newswire
PRNewswire/ -- The Danish, pharmaceutical company ALK (ALKB:DC / OMX: ALK B / AKBLF), today announced it has successfully completed its...
4 months ago
Researchers discover new cell that remembers allergies
Medical Xpress
Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abello A/S have made a groundbreaking discovery: a new...
3 months ago
ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143
Simply Wall Street
It's been a pretty great week for ALK-Abelló A/S ( CPH:ALK B ) shareholders, with its shares surging 14% to kr.149 in...
2 weeks ago
Researchers discover new type of memory B cell that remembers allergies
PharmaTimes
Researchers from McMaster University and the pharmaceutical company ALK-Abello have discovered a new type of cell that remembers allergies.
3 months ago
McMaster and ALK researchers discover new cell that remembers allergies
McMaster University
Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abello A/S have made a groundbreaking discovery: a new...
3 months ago
Could Dupixent find a new life targeting 'memory' B cells?
Fierce Biotech
A new discovery might offer some answers about why allergies happen—as well as open up a potential role for approved biologics like Dupixent...
3 months ago
Allergy Immunotherapy Market Growth in Future Scope 2024-2031 |
openPR.com
Press release - Coherent Market Insights - Allergy Immunotherapy Market Growth in Future Scope 2024-2031 | Stallergenes Greer, ALK-Abello...
23 hours ago
ALK Abello delivers 11% revenue growth; operating profit up 120%
The Pharma Letter
ALK Abello delivers 11% revenue growth; operating profit up 120%
8 months ago
ALK upgrades its full-year revenue outlook | GlobeNewswire by notified
NTB Kommunikasjon
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the 2024 full-year financial outlook has been updated. Revenue is now expected to...
3 weeks ago